NCT00305084View on ClinicalTrials.gov

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

May 8, 2007

Study Completion Date

May 8, 2007

Conditions
Cancer
Interventions
DRUG

NGR-hTNF

0.2, 0.4, 0.8 and 1.6 μg/m²as 60-minute intravenous infusion every 3 weeks

DRUG

Doxorubicin

75 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)

Trial Locations (4)

16132

"Azienda Ospedaliera Universitaria San Martino", Genova

20089

Istituto Clinico Humanitas, Rozzano

20132

Fondazione San Raffaele del Monte Tabor, Milan

Unknown

University Medical Centre, Nijmegen, Nijmegen

Sponsors
All Listed Sponsors
lead

AGC Biologics S.p.A.

INDUSTRY